Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 18;14:1744806918801224. doi: 10.1177/1744806918801224

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 9. — ZLc002 synergizes with paclitaxel in 4T1 cells to reduce breast cancer tumor cell line viability. Dose–response matrix for the effect of (a) ZLc002 and (b) paclitaxel in 4T1 cells. Abs EC₅₀, absolute EC₅₀ > 50 µM, reflects little or no inhibition of 4T1 tumor cell viability by ZLc002; Abs EC₅₀, absolute EC₅₀ = 33.5 nM, reflects efficacy of paclitaxel in reducing 4T1 tumor cell viability by 50% of maximum. (c–d) Single-agent and combination responses determined by an MTT viability assay in 4T1 cells. The landscape of the combination responses for ZLc002 and paclitaxel based on the (e) Bliss model, (f) Loewe model, and (g) highest single agent (HSA) model. Each model supports synergism of the combination of ZLc002 with paclitaxel in reducing tumor cell line viability. (n = 7 experiments). HSA: highest single agent.